News Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
2.01 ^USD	-1.95%		-8.43%	-19.28%

Apr. 29	Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	CI
Apr. 16	ADRs End Lower, Purple Biotech Ltd. Declines 29%	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	Apr. 29	CI
ADRs End Lower, Purple Biotech Ltd. Declines 29%	Apr. 16	DJ
ADRs End Lower, Leju Holdings Ltd. Declines 72%	Apr. 12	DJ
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	Apr. 11	DJ
ADRs Close Lower; VIA Optronics AG Declines 30%	Apr. 10	DJ
Top Midday Gainers	Apr. 10	MT
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund	Mar. 26	AQ
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund	Mar. 25	MT
Alterity Therapeutics : Receives a $3.9 million Research & Development Tax Incentive Refund	Mar. 25	PU
Genetic Technologies Appoints CFO	Mar. 25	MT
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K	Mar. 15	PU
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29	CI
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	Feb. 28	CI
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%	Feb. 22	MT
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	Feb. 06	AQ
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	Feb. 06	CI
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation	Feb. 06	MT
Alterity Therapeutics Completes Securities Purchase Plan	Feb. 01	MT
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week	Jan. 29	AQ
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones	Jan. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

Summary

Filters